 Pyrimidines
"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 0 | 1 | | 1991 | 1 | 2 | 3 | | 1992 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 3 | 0 | 3 | | 1996 | 1 | 1 | 2 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 1 | 2 | | 2000 | 2 | 1 | 3 | | 2001 | 1 | 5 | 6 | | 2002 | 27 | 10 | 37 | | 2003 | 51 | 14 | 65 | | 2004 | 42 | 20 | 62 | | 2005 | 32 | 15 | 47 | | 2006 | 40 | 18 | 58 | | 2007 | 60 | 41 | 101 | | 2008 | 57 | 30 | 87 | | 2009 | 74 | 24 | 98 | | 2010 | 66 | 28 | 94 | | 2011 | 56 | 35 | 91 | | 2012 | 48 | 29 | 77 | | 2013 | 47 | 31 | 78 | | 2014 | 46 | 22 | 68 | | 2015 | 45 | 21 | 66 | | 2016 | 37 | 19 | 56 | | 2017 | 41 | 23 | 64 | | 2018 | 14 | 9 | 23 | | 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
-
Burger JA. Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. Clin Cancer Res. 2019 Apr 15; 25(8):2372-2374.
-
Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb; 6(2):e100-e109.
-
Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene. 2019 04; 38(14):2451-2463.
-
Jain N. Selecting Frontline Therapy for CLL in 2018. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):242-247.
-
Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 2019 03; 38(11):1802-1814.
-
Ma J, Huo X, Jarpe MB, Kavelaars A, Heijnen CJ. Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun. 2018 10 01; 6(1):103.
-
Sabath B, Muhammad HA, Balagani A, Ost DE, Vakil E, Ahmed T, Vial MR, Grosu HB. Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study. BMC Cancer. 2018 Oct 01; 18(1):937.
-
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 11 22; 379(21):2027-2039.
-
Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018 10; 19(10):1351-1359.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|